Drug intelligence / Profile preview

B11-FC

Development stage: Phase 2
Lead developer: Gamaleya Center
Modality: Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous, Intramuscular

Overview

B11-FC is a chimeric antibody that combines a camelid VHH (single-domain antibody) called B11 with a human Fc fragment. It is designed to neutralize botulinum neurotoxin type A (BoNT/A), providing protection against botulism. The B11 component specifically binds to BoNT/A, while the human Fc fragment enhances circulation time in blood and improves protective activity. Preclinical studies have shown that B11-FC can protect animals from lethal doses of botulinum toxin at extremely low doses.

Targets

BoNT/A (Botulinum neurotoxin type A)

Beyond the preview

Go deeper on B11-FC.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on B11-FC.

Explore the full profile